Yonsei University
🇰🇷South Korea
- Country
- 🇰🇷South Korea
- Ownership
- Private
- Established
- 1885-01-01
- Employees
- 5K
- Market Cap
- -
- Website
- http://www.yonsei.ac.kr
Comparison of the Clinical Performance and Safety of the Ambu®AuraGainTM Laryngeal Mask in Children Undergoing Surgery in the Supine and Prone Position - A Prospective, Noninferiority Clinical Trial
Completed
- Conditions
- Bone Marrow ExaminationUrologic Surgical ProceduresOrthopedic Surgery
- First Posted Date
- 2022-03-18
- Last Posted Date
- 2024-06-06
- Lead Sponsor
- Yonsei University
- Target Recruit Count
- 126
- Registration Number
- NCT05286021
- Locations
- 🇰🇷
Yonsei University Health System, Severance Hospital, Seoul, Korea, Republic of
Comparison of Quality of Recovery Between Remimazolam and Propofol Anesthesia in Patients Undergoing Arthroscopic Meniscectomy
Not Applicable
Completed
- Conditions
- Adult Patients 19 or Older Scheduled for Elective Arthroscopic Meniscectomy
- Interventions
- First Posted Date
- 2022-03-15
- Last Posted Date
- 2024-07-08
- Lead Sponsor
- Yonsei University
- Target Recruit Count
- 80
- Registration Number
- NCT05280236
- Locations
- 🇰🇷
Yonsei University Health System, Severance Hospital, Seoul, Korea, Republic of
HPV 16-positive and/or HPV 18-positive Recurrent and/or For Patients With Metastatic Head and Neck Cancer to Evaluate GX-188E DNA Vaccination, GX-I7 and Nivolumab Combination Therapy
Phase 2
Recruiting
- Conditions
- Head and Neck Squamous Cell Carcinoma
- Interventions
- Drug: nivolumab-GX-188E-GX-I7
- First Posted Date
- 2022-03-15
- Last Posted Date
- 2023-03-28
- Lead Sponsor
- Yonsei University
- Target Recruit Count
- 21
- Registration Number
- NCT05280457
- Locations
- 🇰🇷
Yonsei University Health System, Severance Hospital, Seoul, Korea, Republic of
Catheter-directed Sclerotherapy Versus Surgical Resecction: Randomized Controlled Trial Comparing Ovarian Function and Therapeutic Efficacy After Treatment of Ovarian Endometrioma
Not Applicable
- Conditions
- Ovarian Endometrioma
- Interventions
- Procedure: catheter-directed sclerotherapyProcedure: surgical resection
- First Posted Date
- 2022-03-15
- Last Posted Date
- 2022-03-15
- Lead Sponsor
- Yonsei University
- Target Recruit Count
- 98
- Registration Number
- NCT05279209
- Locations
- 🇰🇷
Yonsei University Health System, Severance Hospital, Seoul, Korea, Republic of
Lazertinib for Patients With NSCLC Harboring Uncommon EGFR Mutations
- First Posted Date
- 2022-03-14
- Last Posted Date
- 2022-03-14
- Lead Sponsor
- Yonsei University
- Target Recruit Count
- 36
- Registration Number
- NCT05277701
- Locations
- 🇰🇷
Yonsei University Health System, Severance Hospital, Seoul, Korea, Republic of
Study to Evaluate the Safety and Efficacy of Tislelizumab in Combination With Zanidatamab as a 2nd Line in HER2-Positive Advanced Gastric Cancer in K-Umbrella Trial
Phase 2
- Conditions
- HER2-positive Gastric Cancer
- Interventions
- Drug: Tislelizumab+Zanidatamab
- First Posted Date
- 2022-03-08
- Last Posted Date
- 2022-03-08
- Lead Sponsor
- Yonsei University
- Target Recruit Count
- 50
- Registration Number
- NCT05270889
- Locations
- 🇰🇷
Yonsei University Health System, Severance Hospital, Seoul, Korea, Republic of
Nivolumab for Recurrent/Metastatic Carcinosarcoma
- First Posted Date
- 2022-02-04
- Last Posted Date
- 2022-02-04
- Lead Sponsor
- Yonsei University
- Target Recruit Count
- 28
- Registration Number
- NCT05224999
- Locations
- 🇰🇷
Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of
Analgesic Effect of Intrathecal Morphine Combined With Low Dose Local Anesthetics on Postoperative Analgesia After Liver Resection
Not Applicable
Completed
- Conditions
- Patients Receiving Hepatectomy Under General Anesthesia
- Interventions
- First Posted Date
- 2022-01-26
- Last Posted Date
- 2022-01-26
- Lead Sponsor
- Yonsei University
- Target Recruit Count
- 90
- Registration Number
- NCT05208801
- Locations
- 🇰🇷
Yonsei University Health System, Severance Hospital, Seoul, Korea, Republic of
Window of Opportunity Trial of Durvalumab (MEDI4736) to Identify Immune Dynamics in Operable Non-small Cell Lung Cancer (NSCLC) (MIRACLE)
- First Posted Date
- 2022-01-25
- Last Posted Date
- 2022-02-11
- Lead Sponsor
- Yonsei University
- Target Recruit Count
- 25
- Registration Number
- NCT05206812
- Locations
- 🇰🇷
Yonsei University Health System, Severance Hospital, Seoul, Korea, Republic of
Stereotactic Ablative Radiotherapy for Oligometastatic Hepatocellular Carcinoma
Phase 2
- Conditions
- Oligometastasis Hepatocellular Carcinoma
- First Posted Date
- 2021-12-30
- Last Posted Date
- 2022-08-26
- Lead Sponsor
- Yonsei University
- Target Recruit Count
- 40
- Registration Number
- NCT05173610
- Locations
- 🇰🇷
Yonsei University Health System, Severance Hospital, Seoul, Korea, Republic of
© Copyright 2025. All Rights Reserved by MedPath